Endocrine Abstracts

Background: Sodium glucose co-transporter 2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with empagliflozin on biochemical and immunohistochemical markers related to atherosclerosis development in apolipoprotein E knockout [Apo-E(−/−)] mice.Methods: At the ag...